Sort by
Refine Your Search
-
pathophysiological processes remain to be elucidated. By applying spectral flow cytometry and developing a multi-dimensional platform to phenotype microglia, you will aim to identify functional subsets of microglia in
-
biopharmaceuticals. The research at CMB pushes the boundaries of biomolecular and bioinformatics research and engineering technologies. VIB.AI studies fundamental problems in biology by combining machine learning with
-
4 Mar 2025 Job Information Organisation/Company Ghent University Research Field Biological sciences » Other Chemistry » Biochemistry Engineering » Other Medical sciences » Other Technology
-
://www.imec-int.com/en/home ) (prof. C. Fleischmann). Profile You hold a PhD in computer science, physics, mathematics or engineering (or you will have obtained it by the time you start work). You have
-
heterogeneity has been widely studied using transcriptomics approaches, however, the exact microglial subtypes involved in physio and pathophysiological processes remain to be elucidated. By applying spectral
-
their diversity, must integrate and execute a set of common processes to survive and replicate (metabolize nutrients, generate cellular building blocks, maintain cell shape and size, replicate and segregate
-
nature. This means that novel phages need to be found in nature for essentially every clinical case that one aims to treat in this manner. The project in which you will be involved deals with engineering
-
) computer simulations of heliospheric plasma processes with kinetic (PIC) methods and MHD models. The specific goals to be pursued within the 1+1-year period are tied to the aforementioned topics (turbulence
-
Biology, Physics, Mechanical Engineering, or equivalent (or you will have obtained it by the time you start work). You have a strong affinity for research on functional morphology. Your research qualities
-
postdoctoral researcher - molecular mechanisms T-cell leukemia - Diagnostische Wetenschappen (28449)
expertise in genetic engineering, development of high throughput drug screening assays, generation of in vitro and in vivo cancer models to evaluate novel therapeutic strategies to combat aggressive subtypes